comparemela.com

Latest Breaking News On - China meditech - Page 1 : comparemela.com

Bank of America Securities Sticks to Its Buy Rating for HUTCHMED (HCM)

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on HUTCHMED (HCM – Research Report) yesterday and set a price ta.

Goldman Sachs Remains a Hold on HUTCHMED (HCM)

In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED (HCM – Research Report). The company’s.

FDA Approval Sought for Fruquintinib in Refractory Metastatic Colorectal Cancer

A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.

Hutchison China MediTech Limited (HCM) Q4 2020 Earnings Call Transcript

Executive Director and Chief Executive Officer Okay, thank you. This is Christian Hogg, CEO of HUTCHMED. And today, we welcome everybody to this Fiscal Year 2020 Results and Business Update Presentation. On the line I also have Dr. Wei-guo Su, our Chief Scientific Officer and Head of Research and Development; I have Johnny Cheng, our Chief Financial Officer; and I have Dr. Marek Kania, our Chief Medical Officer in the U.S. and Head of our International operations. What I m planning to do today is, given this is an hour-long session, is spend about 30 minutes 25 minutes to 30 minutes on the presentation. I ll go through it relatively quickly as it s all fairly well laid out in our announcement that s just been out for an hour or so and then I ll leave the second half of the hour for Q&A and that s an opportunity for the broader team that we have here to answer any questions that you might have.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.